Nuwellis’ Aquadex SmartFlow therapy shows heart failure reduction in study

Nuwellis (NUWE) highlighted “promising” findings from an updated analysis of the AVOID-HF study, recently published in the Journal of the American College of Cardiology: Heart Failure. The analysis provides new insights suggesting the potential benefits of Aquadex SmartFlow ultrafiltration therapy in managing heart failure. The analysis found that patients treated with Aquadex therapy demonstrated a 60% reduction in heart failure events at 30 days compared to those receiving traditional IV diuretics. The reanalysis demonstrated not only a significant reduction in heart failure events but also suggested trends towards fewer hospitalizations and improved quality of life for those treated with Aquadex therapy over traditional methods. Nuwellis plans to continue its research efforts under its current REVERSE-HF trial to further establish the clinical and economic benefits of ultrafiltration therapy compared to conventional IV diuretic treatments. The complete analysis will be available in the February 2025 issue of JACC: Heart Failure.